 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||
5 April 2005 | Volume 142 Issue 7 | Pages 532-546
Background: In response to the increase in obesity, pharmacologic treatments for weight loss have become more numerous and more commonly used.
Purpose: To assess the efficacy and safety of weight loss medications approved by the U.S. Food and Drug Administration and other medications that have been used for weight loss.
Data Sources: Electronic databases, experts in the field, and unpublished information.
Study Selection: Up-to-date meta-analyses of sibutramine, phentermine, and diethylpropion were identified. The authors assessed in detail 50 studies of orlistat, 13 studies of fluoxetine, 5 studies of bupropion, 9 studies of topiramate, and 1 study each of sertraline and zonisamide. Meta-analysis was performed for all medications except sertraline, zonisamide, and fluoxetine, which are summarized narratively.
Data Extraction: The authors abstracted information about study design, intervention, co-interventions, population, outcomes, and methodologic quality, as well as weight loss and adverse events from controlled trials of medication.
Data Synthesis: All pooled weight loss values are reported relative to placebo. A meta-analysis of sibutramine reported a mean difference in weight loss of 4.45 kg (95% CI, 3.62 to 5.29 kg) at 12 months. In the meta-analysis of orlistat, the estimate of the mean weight loss for orlistat-treated patients was 2.89 kg (CI, 2.27 to 3.51 kg) at 12 months. A recent meta-analysis of phentermine and diethylpropion reported pooled mean differences in weight loss at 6 months of 3.6 kg (CI, 0.6 to 6.0 kg) for phentermine-treated patients and 3.0 kg (CI, –1.6 to 11.5 kg) for diethylpropion-treated patients. Weight loss in fluoxetine studies ranged from 14.5 kg of weight lost to 0.4 kg of weight gained at 12 or more months. For bupropion, 2.77 kg (CI, 1.1 to 4.5 kg) of weight was lost at 6 to 12 months. Weight loss due to topiramate at 6 months was 6.5% (CI, 4.8% to 8.3%) of pretreatment weight. With one exception, long-term studies of health outcomes were lacking. Significant side effects that varied by drug were reported.
Limitations: Publication bias may exist despite a comprehensive search and despite the lack of statistical evidence for the existence of bias. Evidence of heterogeneity was observed for all meta-analyses.
Conclusions: Sibutramine, orlistat, phentermine, probably diethylpropion, bupropion, probably fluoxetine, and topiramate promote modest weight loss when given along with recommendations for diet. Sibutramine and orlistat are the 2 most-studied drugs.
Editors' Notes
Context
Contribution
Implications
–The Editors
Author and Article Information
From the Southern California Evidence-Based Practice Center, which includes RAND Health Division, Santa Monica, and the Greater Los Angeles VA Healthcare System, Los Angeles, California; and Department of Veterans Affairs, Cincinnati, Ohio.
Disclaimer: The authors of this article are responsible for its content. Statements in the report should not be construed as endorsement by the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services of a particular drug, device, test, treatment, or other clinical service.
Acknowledgments: The authors thank Alison Avenell for allowing us access to the National Health Service Health Technology Assessment report.
Grant Support: This article was supported by a contract to the Southern California Evidence-based Practice Center from the Agency for Healthcare Quality and Research.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Zhaoping Li, MD, PhD, West LA Veterans Affairs Medical Center, W111A, 11301 Wilshire Boulevard, Los Angeles, CA 90073.
Current Author Addresses: Drs. Li and Shekelle: West LA Veterans Affairs Medical Center, W111A, 11301 Wilshire Boulevard, Los Angeles, CA 90073.
Dr. Maglione, Mr. Tu, Dr. Mojica, Dr. Shugarman, Ms. Hilton, Ms. Suttorp, and Dr. Morton: RAND, 1776 Main Street, Santa Monica, CA 90407.
Dr. Arterburn: Cincinatti Veterans Affairs Medical Center, 3200 Vine Street, Cincinatti, OH 45220.
Ms. Solomon: Charles Drew University, 1748 East 118th Street, Building N, Los Angeles, CA 90059. CLINICAL GUIDELINES
Meta-Analysis: Pharmacologic Treatment of Obesity
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  S. L. Norris, D. Kansagara, C. Bougatsos, and R. Fu Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, June 3, 2008; 148(11): 855 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Samat, A. Rahim, and A. Barnett Pharmacotherapy for obesity in menopausal women Menopause Int, June 1, 2008; 14(2): 57 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R Desilets, S. Dhakal-Karki, and K. C Dunican Role of Metformin for Weight Management in Patients Without Type 2 Diabetes Ann. Pharmacother., June 1, 2008; 42(6): 817 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Eckel Nonsurgical Management of Obesity in Adults N. Engl. J. Med., May 1, 2008; 358(18): 1941 - 1950. [Full Text] [PDF]
|
|
|
|
 |
|
 K M Klein, F Theisen, S Knake, W H Oertel, J Hebebrand, F Rosenow, and H M Hamer Topiramate, nutrition and weight change: a prospective study J. Neurol. Neurosurg. Psychiatry, May 1, 2008; 79(5): 590 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Tizzano, D. S. Stribling, D. Perez-Tilve, A. Strack, A. Frassetto, R. Z. Chen, T. M. Fong, L. Shearman, P. A. Krieter, M. H. Tschop, et al. The Triple Uptake Inhibitor (1R,5S)-(+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0] Hexane Hydrochloride (DOV 21947) Reduces Body Weight and Plasma Triglycerides in Rodent Models of Diet-Induced Obesity J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1111 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Shirali and M. J. Bia Management of Cardiovascular Disease in Renal Transplant Recipients Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 491 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J F Bult, T. van Dalen, and A. F Muller Surgical treatment of obesity Eur. J. Endocrinol., February 1, 2008; 158(2): 135 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rucker, R. Padwal, S. K Li, C. Curioni, and D. C W Lau Long term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ, December 8, 2007; 335(7631): 1194 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. O'Neil and T. A. Nicklas State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health American Journal of Lifestyle Medicine, December 1, 2007; 1(6): 457 - 481. [Abstract] [PDF]
|
|
|
|
 |
|
 M. M. Huizinga Weight-Loss Pharmacotherapy: A Brief Review Clin. Diabetes, October 1, 2007; 25(4): 135 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Kamiji and A. Inui Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity Endocr. Rev., October 1, 2007; 28(6): 664 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W Anderson, S. B Conley, and A. S Nicholas One hundred pound weight losses with an intensive behavioral program: changes in risk factors in 118 patients with long-term follow-up Am. J. Clinical Nutrition, August 1, 2007; 86(2): 301 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Bray and F. L. Greenway Pharmacological Treatment of the Overweight Patient Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Christensen, E. M. Bartels, A. Astrup, and H. Bliddal Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis Ann Rheum Dis, April 1, 2007; 66(4): 433 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Patel and R. Pathak Rimonabant: A novel selective cannabinoid-1 receptor antagonist for treatment of obesity Am. J. Health Syst. Pharm., March 1, 2007; 64(5): 481 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fujioka and M. W. Lee Pharmacologic Treatment Options for Obesity: Current and Potential Medications Nutr Clin Pract, February 1, 2007; 22(1): 50 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Freemark Pharmacotherapy of Childhood Obesity: An evidence-based, conceptual approach Diabetes Care, February 1, 2007; 30(2): 395 - 402. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Byers and R. L. Sedjo Public Health Response to the Obesity Epidemic: Too Soon or Too Late? J. Nutr., February 1, 2007; 137(2): 488 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M H Bennett, S. Mehta, and M. Rhodes Surgery for morbid obesity Postgrad. Med. J., January 1, 2007; 83(975): 8 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Goren Hyperthyroidism Associated With Topiramate Treatment Psychosomatics, December 1, 2006; 47(6): 529 - 530. [Full Text] [PDF]
|
|
|
|
|
|
K. E. Foster-Schubert and D. E. Cummings Emerging Therapeutic Strategies for Obesity Endocr. Rev., December 1, 2006; 27(7): 779 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lopez, C. J. Lelliott, S. Tovar, W. Kimber, R. Gallego, S. Virtue, M. Blount, M. J. Vazquez, N. Finer, T. J. Powles, et al. Tamoxifen-Induced Anorexia Is Associated With Fatty Acid Synthase Inhibition in the Ventromedial Nucleus of the Hypothalamus and Accumulation of Malonyl-CoA. Diabetes, May 1, 2006; 55(5): 1327 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chounta, S. Tsiodras, S. Zouridakis, M. Doumas, and H. Giamarellou Sibutramine Use Associated with Reversible Hepatotoxicity Ann Intern Med, November 15, 2005; 143(10): 763 - 764. [Full Text] [PDF]
|
|
|
|
|
|
D. T Villareal, C. M Apovian, R. F Kushner, and S. Klein Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society Am. J. Clinical Nutrition, November 1, 2005; 82(5): 923 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Dixon, M. E. Dixon, and P. E. O'Brien Birth Outcomes in Obese Women After Laparoscopic Adjustable Gastric Banding Obstet. Gynecol., November 1, 2005; 106(5): 965 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Wolfe and J. M. Morton Weighing In on Bariatric Surgery: Procedure Use, Readmission Rates, and Mortality JAMA, October 19, 2005; 294(15): 1960 - 1963. [Full Text] [PDF]
|
|
|
|
 |
|
 K. A Kennel Review: several pharmacological therapies promote modest weight loss Evid. Based Med., October 1, 2005; 10(5): 140 - 140. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Robbins Guidelines for the Treatment of Obesity AAP Grand Rounds, September 1, 2005; 14(3): 31 - 32. [Full Text] [PDF]
|
|
|
|
 |
|
 Endocrinology & Metabolism News, May 2005 J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 16a - 16a. [Full Text] [PDF]
|
|
|
|
 |
|
 Managing Obesity: Clinical Practice Guideline from the ACP Journal Watch (General), April 26, 2005; 2005(426): 1 - 1. [Full Text]
|
|
|
|
|
|
A. Tonks Short cuts: What's new in the other general journals BMJ, April 16, 2005; 330(7496): 867 - 868. [Full Text] [PDF]
|
|
|
|
|
|
V. Snow, P. Barry, N. Fitterman, A. Qaseem, K. Weiss, and for the Clinical Efficacy Assessment Subcommittee Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, April 5, 2005; 142(7): 525 - 531. [Abstract] [Full Text] [PDF]
|
|
Read all Rapid Responses
Article
